Lumiliximab

Lumiliximab is a monoclonal antibody designed for the treatment of B-cell chronic lymphocytic leukemia. It was developed by Biogen Idec, a biotechnology company based in the United States. Lumiliximab works by targeting a specific protein found on the surface of B cells, known as CD23, and inducing cell death.

Mechanism of Action

Lumiliximab is a monoclonal antibody that targets the CD23 protein. This protein is overexpressed in B-cell chronic lymphocytic leukemia, making it a suitable target for therapy. By binding to CD23, Lumiliximab triggers a process known as antibody-dependent cellular cytotoxicity, which leads to the destruction of the cancer cells.

Clinical Trials

Lumiliximab has been tested in several clinical trials. In a Phase II trial, it was combined with fludarabine, cyclophosphamide, and rituximab, a regimen known as FCR. The results showed that the addition of Lumiliximab to FCR did not improve the overall response rate or progression-free survival compared to FCR alone.

Development and Approval

The development of Lumiliximab was discontinued in 2008 after it failed to meet its primary endpoint in a Phase III trial. Despite this, the drug has been the subject of ongoing research, particularly in combination with other therapies.

See Also

• Monoclonal antibodies
• B-cell chronic lymphocytic leukemia
• CD23
• Biogen Idec

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian